9 completed, 5 active not recruiting, 2 recruiting, 1 terminated. 17 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 9, Active not recruiting 5, Recruiting 2, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
Follow Prostate Adenocarcinoma: new trials by email Literature Review of Prostate Adenocarcinoma trials Research Report on Prostate Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer Copper Cu 64 PSMA I&T - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Completed | Curium US LLC | 235 | 2024-04-01 | 2026-02-18 |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer Copper Cu 64 PSMA I&T - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Active not recruiting | Curium US LLC | 439 | 2024-04-01 | 2026-10-27 |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 1500 | 2023-12-14 | 2026-10-23 |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial Bicalutamide, Buserelin, Darolutamide - Prostate Adenocarcinoma | Phase 3 | Active not recruiting | NRG Oncology | 2050 | 2021-12-06 | 2026-08-17 |
| 68Ga-PSMA-11 PET in Patients With Prostate Cancer Ga-PSMA-11 - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Completed | University of Colorado, Denver | 39 | 2021-09-29 | 2023-11-13 |
| Ga-68-PSMA-11 in Men With Prostate Cancer Ga-68-PSMA-11 - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Terminated | Timothy Hoffman | 38 | 2021-07-27 | 2023-02-24 |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 2753 | 2021-01-21 | 2026-08-17 |
| Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Cabozantinib, Atezolizumab, Abiraterone Acetate - Metastatic Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Active not recruiting | Exelixis | 575 | 2020-10-19 | 2025-12-18 |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 804 | 2020-10-08 | 2026-11-13 |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial Apalutamide, Biospecimen Collection, Bone Scan - Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 586 | 2020-04-16 | 2026-11-18 |
| Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer 18F-DCFPyL, PET/CT Imaging - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Completed | Progenics Pharmaceuticals, Inc. | 208 | 2018-11-27 | 2021-06-14 |
| Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI C-11 choline PET tracer, Gadobutrol, PET/MR scanner - Prostate Adenocarcinoma | Phase 3 | Completed | Mayo Clinic | 19 | 2017-11-01 | 2021-02-08 |
| Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7 | Phase 3 | Completed | NRG Oncology | 296 | 2017-07-28 | 2026-07-09 |
| 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET) - Prostate Adenocarcinoma, PSA Failure | Phase 2 / Phase 3 | Completed | Andrei Iagaru | 61 | 2017-05-20 | 2022-01-13 |
| Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography - Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | Phase 3 | Completed | Jonsson Comprehensive Cancer Center | 1138 | 2016-09-15 | 2021-07-02 |
| 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer 68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography - Prostate Adenocarcinoma | Phase 2 / Phase 3 | Completed | Andrei Iagaru | 122 | 2015-11-16 | 2023-04-10 |
| Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer Short term androgen deprivation, Long term androgen deprivation - Prostate Adenocarcinoma | Phase 3 | Completed | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | 362 | 2005-11-01 | 2020-11-20 |
Prostatic Neoplasms (13) · Disease (1)
Genital Diseases (13) · Genital Diseases, Male (13) · Genital Neoplasms, Male (13) · Male Urogenital Diseases (13) · Neoplasms (13) · Neoplasms by Site (13) · Prostatic Diseases (13) · Urogenital Diseases (13) · Urogenital Neoplasms (13) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Magnetic Resonance Spectroscopy (7) · Radiation (6) · Radiotherapy (4) · Goserelin (3) · Leuprolide (3) · Specimen Handling (3) · Triptorelin Pamoate (3) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (3) · apalutamide (3) · gallium 68 PSMA-11 (3) · relugolix (3) · Buserelin (2) · Congresses as Topic (2) · Flutamide (2) · Radiosurgery (2)
NRG Oncology (5) · Andrei Iagaru (2) · Curium US LLC (2) · ECOG-ACRIN Cancer Research Group (1) · Exelixis (1) · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · Progenics Pharmaceuticals, Inc. (1) · Timothy Hoffman (1) · University of Colorado, Denver (1)
United States (16) · Canada (7) · Singapore (2) · Spain (2) · Switzerland (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Chile (1) · Czechia (1) · France (1) · Georgia (1) · Germany (1)
Almudena Zapatero, MD PhD, IP (1) · Andrei Iagaru (1) · Andrei Iagaru, MD (1) · Bennett Chin (1) · Jessica D Jensen (1) · Johannes Czernin, MD (1) · Karen E Hoffman (1) · Mark K Buyyounouski (1) · Ming Yang (1) · Neha Vapiwala (1) · Neil B Desai (1) · Paul L Nguyen (1) · Ronald C Chen (1) · Timothy J Hoffman, PhD (1)
PMID 38421243, PMID 16170164, PMID 25702876, PMID 27598804, PMID 29242398, PMID 29242404, PMID 30920593, PMID 31375469, PMID 31478089, PMID 32808077, PMID 33674398, PMID 34406051, PMID 35034502, PMID 35427469, PMID 37555901, PMID 38423030, PMID 38483412, PMID 40523369, PMID 41698328, PMID 41806372
U10CA180868 (5), U10CA180820 (1)